Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Summary of the Chronic Obstructive Pulmonary Disease Clinical Practice Guideline Revised in 2014 by the Korean Academy of Tuberculosis and Respiratory Disease

  • Yoon, Hyoung Kyu (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Park, Yong-Bum (Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital) ;
  • Rhee, Chin Kook (Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Lee, Jin Hwa (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Oh, Yeon-Mok (Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Committee of the Korean COPD Guideline 2014 (Committee of the Korean COPD Guideline 2014)
  • Received : 2016.10.14
  • Accepted : 2017.03.10
  • Published : 2017.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Chronic obstructive pulmonary disease (COPD) results in high morbidity and mortality among patients both domestically and globally. The Korean clinical practice guideline for COPD was revised in 2014. It was drafted by the members of the Korean Academy of Tuberculosis and Respiratory Diseases, as well as participating members of the Health Insurance Review and Assessment Service, Korean Physicians' Association, and Korea Respiration Trouble Association. This revised guideline covers a wide range of topics, including the epidemiology, diagnosis, assessment, monitoring, management, exacerbation, and comorbidities of COPD in Korea. We drafted a guideline on COPD management by performing systematic reviews on the topic of management with the help of a meta-analysis expert. We expect this guideline will be helpful medical doctors treating patients with respiratory conditions, other health care professionals, and government personnel in South Korea.

Keywords

References

  1. Kim C, Yoo KH, Rhee CK, Yoon HK, Kim YS, Lee SW, et al. Health care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea. Int J Tuberc Lung Dis 2014;18:737-43. https://doi.org/10.5588/ijtld.13.0634
  2. Statistics Korea. The result of causes of death statistics in 2010. Daejeon: Statistics Korea; 2011.
  3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442. https://doi.org/10.1371/journal.pmed.0030442
  4. Korean Academy of Tuberculosis and Respiratory Diseases. COPD clinical practice guidelines revised in 2014 [Internet]. Seoul: Korean Academy of Tuberculosis and Respiratory Diseases; 2014 [cited 2017 May 1]. Available from: http://www.lungkorea.org/bbs/index.html?code=guide&page=2.
  5. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397-412. https://doi.org/10.1183/09031936.06.00025805
  6. Bousquet J, Kiley J, Bateman ED, Viegi G, Cruz AA, Khaltaev N, et al. Prioritised research agenda for prevention and control of chronic respiratory diseases. Eur Respir J 2010;36:995-1001. https://doi.org/10.1183/09031936.00012610
  7. Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology 2011;16:659-65. https://doi.org/10.1111/j.1440-1843.2011.01951.x
  8. Statistics Korea. 2010 Morbidity statistics on causes of death among Koreans. Daejeon: Statistics Korea; 2011.
  9. Oh IH, Yoon SJ, Kim EJ. The burden of disease in Korea. J Korean Med Assoc 2011;54:646-52. https://doi.org/10.5124/jkma.2011.54.6.646
  10. Lamprecht B, McBurnie MA, Vollmer WM, Gudmundsson G, Welte T, Nizankowska-Mogilnicka E, et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 2011;139:752-63. https://doi.org/10.1378/chest.10-1253
  11. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:693-718. https://doi.org/10.1164/rccm.200811-1757ST
  12. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003;22:672-88. https://doi.org/10.1183/09031936.03.00040703
  13. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65. https://doi.org/10.1164/rccm.201204-0596PP
  14. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303. https://doi.org/10.1136/bmj.320.7245.1297
  15. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-505. https://doi.org/10.1001/jama.1994.03520190043033
  16. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Longterm effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23. https://doi.org/10.1016/S0140-6736(98)10019-3
  17. Sestini P, Cappiello V, Aliani M, Martucci P, Sena A, Vaghi A, et al. Prescription bias and factors associated with improper use of inhalers. J Aerosol Med 2006;19:127-36. https://doi.org/10.1089/jam.2006.19.127
  18. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010;182:155-62. https://doi.org/10.1164/rccm.200910-1500OC
  19. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37:273-9. https://doi.org/10.1183/09031936.00045810
  20. Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;(2):CD002876.
  21. Kesten S, Casaburi R, Kukafka D, Cooper CB. Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis 2008;3:127-36. https://doi.org/10.2147/COPD.S2389
  22. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54. https://doi.org/10.1056/NEJMoa0805800
  23. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;(9):CD009157.
  24. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, Beeh KM, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093-103. https://doi.org/10.1056/NEJMoa1008378
  25. Jones PW, Singh D, Bateman ED, Agusti A, Lamarca R, de Miquel G, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012;40:830-6. https://doi.org/10.1183/09031936.00225511
  26. Kerwin E, Hebert J, Gallagher N, Martin C, Overend T, Alagappan VK, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012;40:1106-14. https://doi.org/10.1183/09031936.00040712
  27. Beier J, Kirsten AM, Mroz R, Segarra R, Chuecos F, Caracta C, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-tosevere chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD 2013;10:511-22. https://doi.org/10.3109/15412555.2013.814626
  28. D'Urzo A, Kerwin E, Rennard S, He T, Gil EG, Caracta C. Oneyear extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD. COPD 2013;10:500-10. https://doi.org/10.3109/15412555.2013.791809
  29. Gelb AF, Tashkin DP, Make BJ, Zhong X, Garcia Gil E, Caracta C, et al. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD. Respir Med 2013;107:1957-65. https://doi.org/10.1016/j.rmed.2013.07.001
  30. Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis 2012;7:503-13.
  31. Chapman KR, Beeh KM, Beier J, Bateman ED, D'Urzo A, Nutbrown R, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med 2014;14:4. https://doi.org/10.1186/1471-2466-14-4
  32. D'Urzo A, Kerwin E, Overend T, D'Andrea P, Chen H, Goyal P. Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies. Curr Med Res Opin 2014;30:493-508. https://doi.org/10.1185/03007995.2013.858618
  33. ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119:1661-70. https://doi.org/10.1378/chest.119.6.1661
  34. Rodrigo GJ, Plaza V. Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review. Chest 2014;146:309-17. https://doi.org/10.1378/chest.13-2807
  35. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199-209. https://doi.org/10.1016/S2213-2600(13)70052-3
  36. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81. https://doi.org/10.1183/09031936.03.00031402
  37. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56. https://doi.org/10.1016/S0140-6736(03)12459-2
  38. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89. https://doi.org/10.1056/NEJMoa063070
  39. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-53. https://doi.org/10.1056/NEJM199906243402503
  40. Karner C, Cates CJ. Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011;(3):CD008532.
  41. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-71. https://doi.org/10.1016/S0140-6736(05)67100-0
  42. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94. https://doi.org/10.1016/S0140-6736(09)61255-1
  43. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-61. https://doi.org/10.1164/rccm.200610-1563OC
  44. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, et al. Roflumilast in moderate-tosevere chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703. https://doi.org/10.1016/S0140-6736(09)61252-6
  45. Rice KL, Kronenberg RS, Hedemark LL, Niewoehner DE. Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Br J Dis Chest 1987;81:287-92. https://doi.org/10.1016/0007-0971(87)90163-X
  46. Chong J, Poole P, Leung B, Black PN. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011;(5):CD002309.
  47. Bateman ED, Rabe KF, Calverley PM, Goehring UM, Brose M, Bredenbroker D, et al. Roflumilast with long-acting beta2-agonists for COPD: influence of exacerbation history. Eur Respir J 2011;38:553-60. https://doi.org/10.1183/09031936.00178710
  48. Lee SD, Hui DS, Mahayiddin AA, Roa CC Jr, Kwa KH, Goehring UM, et al. Roflumilast in Asian patients with COPD: a randomized placebo-controlled trial. Respirology 2011;16:1249-57. https://doi.org/10.1111/j.1440-1843.2011.02038.x
  49. Ni W, Shao X, Cai X, Wei C, Cui J, Wang R, et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PLoS One 2015;10:e0121257. https://doi.org/10.1371/journal.pone.0121257
  50. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178:1139-47. https://doi.org/10.1164/rccm.200801-145OC
  51. Sethi S, Jones PW, Theron MS, Miravitlles M, Rubinstein E, Wedzicha JA, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010;11:10. https://doi.org/10.1186/1465-9921-11-10
  52. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98. https://doi.org/10.1056/NEJMoa1104623
  53. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006;173:1390-413. https://doi.org/10.1164/rccm.200508-1211ST
  54. Stoller JK, Panos RJ, Krachman S, Doherty DE, Make B; Longterm Oxygen Treatment Trial Research Group. Oxygen therapy for patients with COPD: current evidence and the longterm oxygen treatment trial. Chest 2010;138:179-87. https://doi.org/10.1378/chest.09-2555
  55. Sciurba FC, Ernst A, Herth FJ, Strange C, Criner GJ, Marquette CH, et al. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med 2010;363:1233-44. https://doi.org/10.1056/NEJMoa0900928
  56. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD [Internet]. Global Initiative for Chronic Obstructive Lung Disease; 2015 [cited 2015 Jun 1]. Available from: http://www.goldcopd.com/guidelines-global-strategyfor-diagnosis-management.html.
  57. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007;370:786-96. https://doi.org/10.1016/S0140-6736(07)61382-8
  58. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008;359:2355-65. https://doi.org/10.1056/NEJMra0800353
  59. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204. https://doi.org/10.7326/0003-4819-106-2-196
  60. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006;28:1245-57. https://doi.org/10.1183/09031936.00133805
  61. Almagro P, Cabrera FJ, Diez J, Boixeda R, Alonso Ortiz MB, Murio C, et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study. Chest 2012;142:1126-33. https://doi.org/10.1378/chest.11-2413
  62. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204-12. https://doi.org/10.1183/09031936.00114307
  63. Salpeter S, Ormiston T, Salpeter E. Cardioselective betablockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;(4):CD003566.
  64. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010;55:1780-7. https://doi.org/10.1016/j.jacc.2010.01.024
  65. Cao C, Wang R, Wang J, Bunjhoo H, Xu Y, Xiong W. Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. PLoS One 2012;7:e43892. https://doi.org/10.1371/journal.pone.0043892
  66. Yamauchi Y, Hasegawa W, Yasunaga H, Sunohara M, Jo T, Takami K, et al. Paradoxical association between body mass index and in-hospital mortality in elderly patients with chronic obstructive pulmonary disease in Japan. Int J Chron Obstruct Pulmon Dis 2014;9:1337-46.
  67. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38. https://doi.org/10.1056/NEJMoa0909883
  68. Kim J, Lee JH, Kim Y, Kim K, Oh YM, Yoo KH, et al. Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study. BMC Pulm Med 2013;13:51. https://doi.org/10.1186/1471-2466-13-51
  69. Martinez CH, Okajima Y, Murray S, Washko GR, Martinez FJ, Silverman EK, et al. Impact of self-reported gastroesophageal reflux disease in subjects from COPDGene cohort. Respir Res 2014;15:62. https://doi.org/10.1186/1465-9921-15-62
  70. Ferguson GT, Calverley PM, Anderson JA, Jenkins CR, Jones PW, Willits LR, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009;136:1456-65. https://doi.org/10.1378/chest.08-3016
  71. Madsen H, Brixen K, Hallas J. Screening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease: a population-based database study. Clin Respir J 2010;4:22-9. https://doi.org/10.1111/j.1752-699X.2009.00138.x
  72. Kunik ME, Roundy K, Veazey C, Souchek J, Richardson P, Wray NP, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005;127:1205-11.
  73. Chin HJ, Lee KH, Park CS, Son CW, Lee HY, Yu SK, et al. Prevalence and risk factors of depression in patients with chronic obstructive pulmonary disease. Tuberc Respir Dis 2008;65:191-7. https://doi.org/10.4046/trd.2008.65.3.191
  74. Ryu YJ, Chun EM, Lee JH, Chang JH. Prevalence of depression and anxiety in outpatients with chronic airway lung disease. Korean J Intern Med 2010;25:51-7. https://doi.org/10.3904/kjim.2010.25.1.51
  75. Hwang YI, Lee YS, Oh YM, Lee SD, Park SW, Kim YS, et al. Prevalence of depression and its influence on health-related quality of life in COPD patients. Chest 2011;140:542A. https://doi.org/10.1378/chest.1118016
  76. Hwang YI, Kim, HJ, Won WY, Joh JS, Oh YM, Jung KS, et al. Screening for depression in patients with chronic obstructive pulmonary disease: a systematic review. Korean J Med 2012;83:468-75. https://doi.org/10.3904/kjm.2012.83.4.468
  77. Choi HS, Choi JH, Park KH, Joo KJ, Ga H, Ko HJ, et al. Standardization of the Korean Version of Patient Health Questionnaire- 9 as a screening instrument for major depressive disorder. J Korean Acad Fam Med 2007;28:114-9.
  78. Lim KH, Park YN, Kim DH, Shin IH, Lee WS, Kim JB. A preliminary study of the standardization of the Korean Version of the Patient Health Questionnaire-9. Korean J Health Promot Dis Prev 2009;9:275-81.
  79. Anthonisen NR, Connett JE, Enright PL, Manfreda J; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166:333-9. https://doi.org/10.1164/rccm.2110093
  80. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409. https://doi.org/10.1056/NEJMoa1102873
  81. Benfield T, Lange P, Vestbo J. COPD stage and risk of hospitalization for infectious disease. Chest 2008;134:46-53. https://doi.org/10.1378/chest.07-2933
  82. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;(3):CD010115.

Cited by

  1. Adherence to Inhaled Medications and its Effect on Healthcare Utilization and Costs Among High-Grade Chronic Obstructive Pulmonary Disease Patients vol.38, pp.4, 2017, https://doi.org/10.1007/s40261-017-0612-2
  2. Significant predictors of medically diagnosed chronic obstructive pulmonary disease in patients with preserved ratio impaired spirometry: a 3-year cohort study vol.19, pp.None, 2017, https://doi.org/10.1186/s12931-018-0896-7
  3. Comparison of the effects of different-sized airways in inspiratory trainers on maximal inspiratory pressure and rating of perceived exertion scale in healthy young people vol.7, pp.1, 2017, https://doi.org/10.14474/ptrs.2018.7.1.18
  4. What Can We Apply to Manage Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Acute Respiratory Failure? vol.81, pp.2, 2018, https://doi.org/10.4046/trd.2017.0094
  5. Optimal Bronchodilation for COPD Patients: Are All Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonists the Same? vol.81, pp.3, 2018, https://doi.org/10.4046/trd.2018.0040
  6. The diagnosis of chronic obstructive pulmonary disease according to current guidelines vol.61, pp.9, 2017, https://doi.org/10.5124/jkma.2018.61.9.539
  7. Increased Risk of Exacerbation in Asthma Predominant Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome vol.81, pp.4, 2017, https://doi.org/10.4046/trd.2017.0064
  8. PI3K Signaling in Chronic Obstructive Pulmonary Disease: Mechanisms, Targets, and Therapy vol.26, pp.16, 2019, https://doi.org/10.2174/0929867325666180320120054
  9. Direct and Indirect Costs of Chronic Obstructive Pulmonary Disease in Korea vol.82, pp.1, 2017, https://doi.org/10.4046/trd.2018.0035
  10. ILC2s Induce Adaptive Th2-Type Immunity in Acute Exacerbation of Chronic Obstructive Pulmonary Disease vol.2019, pp.None, 2017, https://doi.org/10.1155/2019/3140183
  11. Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives vol.36, pp.3, 2017, https://doi.org/10.1007/s12325-019-0893-3
  12. Outcome of Regular Inhaled Treatment in GOLD A Chronic Obstructive Pulmonary Disease Patients vol.98, pp.4, 2017, https://doi.org/10.1159/000495756
  13. Risk of acute exacerbations in chronic obstructive pulmonary disease associated with biomass smoke compared with tobacco smoke vol.19, pp.None, 2017, https://doi.org/10.1186/s12890-019-0833-7
  14. Progression of erectile function in men with chronic obstructive pulmonary disease: a cohort study vol.19, pp.1, 2017, https://doi.org/10.1186/s12890-019-0902-y
  15. Correlation between TNF-α -308 and +489 Gene Polymorphism and Acute Exacerbation of Chronic Obstructive Pulmonary Diseases vol.2021, pp.None, 2017, https://doi.org/10.1155/2021/6661281
  16. Promising Expectations for Pneumococcal Vaccination during COVID-19 vol.9, pp.12, 2017, https://doi.org/10.3390/vaccines9121507
  17. The Long-term Efficacy of Domiciliary Noninvasive Positive-Pressure Ventilation in Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials vol.85, pp.1, 2017, https://doi.org/10.4046/trd.2021.0062